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Janssen-Cilag has revised the prescribing information in the
package insert for Eprex (recombinant human erythropoietin
alfa) to include the following statements:
‘In patients with chronic renal failure, Eprex should only be
administered by the intravenous route’, 
and 
‘If PRCA is diagnosed, therapy with Eprex must be immediately
discontinued and testing for erythropoietin antibodies should be
considered. Patients should not be switched to another product as
anti-erythopoietin antibodies cross-react with other erythropoietins.
Other causes of PRCA should be excluded and appropriate therapy
instituted.’
Changes to the prescribing information for Eprex have been
made as a result of investigations into cases of pure red cell
aplasia (PRCA), erythroblastopenia) associated with the use of
erythropoietin. In patients with chronic renal failure Eprex
should only be administered by the intravenous route.
International statistics
Cases of antibody-positive PRCA have been reported from
post-marketing experience in patients with chronic renal failure
(CRF). As of 30 September 2002, the company had received 155
reports of PRCA confirmed by bone marrow biopsy
worldwide. All cases were limited to patients with chronic
renal failure. Of these cases 112 tested positive for the presence
of antierythropoietin antibodies, and in the remaining 43 cases,
the antibody status was unknown. All patients with
antierythropoietin antibodies had received Eprex via the
subcutaneous route of administration, where the route of
administration was known. Lack of efficacy was first noted
between 4 and 24 months after the start of treatment with
Eprex, in those patients who tested positive for
antierythropoietin antibodies. In addition, there has been a
report of PRCA in a patient who received repeated doses of
Eprex subcutaneously for refractory anaemia in an unlicensed
indication.
Of the total number of cases reported to date, there has been
a subset of antibody-mediated PRCA cases (17/112) in patients
exposed to other erythropoietin products in conjunction with
Eprex. Janssen-Cilag has embarked on an extensive
epidemiological study as part of the clinical programme to
monitor and evaluate the occurrence of antibody-mediated
PRCA associated with epoetinums in patients with chronic
renal failure.
National statistics
The National Adverse Drug Event Monitoring Centre of the
Medicines Control Council has 5 reports of lack of efficacy
associated with the use of Eprex. All the patients had CRF and
were being treated with subcutaneous Eprex. The details are
set out below.
Recommendation
It is recommended that clinicians review the management of
patients with chronic renal failure being treated with Eprex.
Eprex administration may be continued in these patients, but
only via the intravenous route. When changing from
subcutaneous to intravenous administration, the same dose of
Eprex should be used and the haemoglobin monitored
carefully (e.g. weekly) so that appropriate changes to the dose
can be made to keep the haemoglobin within the target range.
National Adverse Drug Event Monitoring Centre
Medicines Control Council
1. ADRI database, National Adverse Drug Event Monitoring Centre, Medicines Control
Council.
2. Eprex package insert.
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Patient aspirate antibodies Outcome
1 Positive Positive Died due to disease 
progression
2 Positive Negative Unknown
3 Not done Not done Recovered from 
septicaemia
4 Not done Not done Unknown — awaiting
feedback from
reporter
5 Positive Positive Unknown
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